Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT04179695
Recruiting Not applicable

Evaluation of a New Communication Aid Tool to Favor Global Patient Centered Care

NCT04179695 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Lille
Phase
Not applicable
Started
2020-07-21
Last updated
2025-12-23

Condition(s) studied

Parkinson's Disease

Investigational drug(s) / intervention(s)

Consulting with PARKINSUN as communication aid-toolConsulting without PARKINSUN as communication aid-tool

Consulting with PARKINSUN as communication aid-tool: Participating patients visit their general practitioner or neurologist with PARKINSUN at 1 months, 4 months, 7 months

Consulting without PARKINSUN as communication aid-tool: Participating patients visit their general practitioner or neurologist without PARKINSUN at 1 months, 4 months, 7 months

Study summary

PARKINSUN is a new communication aid tool, expected to favor global patient centered care for PD patients during consultation with GPs and neurologists. Two groups of patients will be randomized to use or not PARKINSUN when they consult their physicians every 3 months during 7 months.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * Adult men and women with all stages of PD * Without severe chronic neurological or mental or psychiatric pathology * Absence of cognitive impairment affecting autonomy (MDS criteria of dementia and MOCA \> 22) * able to come (alone or accompanied) to consultation * Affiliate or beneficiary of a social security scheme * Subject having signed informed consent * Patient willing to comply with all procedures of the study and its duration Exclusion Criteria: * Administrative reasons: impossibility of receiving informed information, inability to participate in the whole study, absence of coverage by the social security system, refusal to sign consent. * Subject under tutelage or curtailer. * Subject not fluent in the French language to understand the instructions necessary to carry out the cognitive tests.

Primary outcome measure(s)

  • variation of the delta of G-MISS Questionnaire — at 7 months

Trial sites (1)

FacilityCityRegionStatus
Hopital Roger Salengro, CHU Lille Lille France Recruiting

More University Hospital, Lille trials in France

Antibiotic Strategy and Asymptomatic Bacteriuria in the Context of Intra-vesical Botulinum Toxin A Injections. Starting soon
Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO Recruiting
Effectiveness of Erector Spinae Plane Block for Percutaneous Arthrodesis of Spinal Fractures Active, not recruiting
Performance of Carbon Dioxide (CO2)-Derived Parameters in Predicting Low Cardiac Output Syndrome Recruiting
Bone Marrow Fat and Bariatric Surgery-Mediated Bone Loss Recruiting

Other trials for the same condition

Combined Genome and RNA Sequencing for Genetic Diagnosis of Parkinsonism Recruiting
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease Active, not recruiting
Prevent Cognitive Decline in GBA-associated Parkinson's Disease Starting soon
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry Recruiting
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04179695 on ClinicalTrials.gov ↗ ← All trials in France